Discordant responses on starting highly active antiretroviral therapy: Suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study

HIV Medicine

Volumn 11, Issue 2, 2010, Pages 152-160

  Gilson, R ^a,b   Man, S L ^a,b   Copas, A ^b   Rider, A ^a,b   Forsyth, S ^a   Hill, T ^b   Bansi, L ^b   Porter, K ^c   Gazzard, B ^d   Orkin, C ^e   Pillay, D ^b   Schwenk, A ^f   Johnson, M ^g   Easterbook, P ^h   Walsh, J ⁱ   Fisher, M ^j   Leen, C ^k   Anderson, J ^l   Sabin, C A ^b  

^a Camden Primary Care Trust   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e BARTS HEALTH NHS TRUST   (United Kingdom)

^f NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^g ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ ST MARY S HOSPITAL   (United Kingdom)

^j Worthing Hospital   (United Kingdom)

^k WESTERN GENERAL HOSPITAL   (United Kingdom)

^l HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

Antiviral therapy; CD4 lymphocyte count; Discordant response; HIV; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 73549094243     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00755.x     Document Type: Article

References (20)

1. Wood E, Yip B, Hogg RS. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000, 14:1955-1960.
2. Piketty C, Castiel P, Belec L. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12:745-750.
3. Grabar S, Le Moing V, Goujard C. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133:401-410.
4. Kaufmann GR, Furrer H, Ledergerber B. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005, 41:361-372.
5. Wood E, Hogg RS, Yip B. 'Discordant' increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 30:159-166.
6. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001, 183:1328-1335.
7. Chan KC, Yip B, Hogg RS, Montaner JS, O'Shaughnessy MV. Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 2002, 16:1693-1695.
8. Florence E, Lundgren J, Dreezen C. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA Study. HIV Med 2003, 4:255-262.
9. Kaufmann GR, Perrin L, Pantaleo G. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Int Med 2003, 163:2187-2195.
10. Sufka SA, Ferrari G, Gryszowka VE. Prolonged CD4 cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis 2003, 187:1027-1037.
11. Solomon A, Cameron PU, Bailey M. Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis 2003, 187:1915-1923.
12. Moore DM, Hogg RS, Yip B. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005, 40:288-293.
13. Molina Pinelo S, Leal M, Soriano Sarabia N. Prevalence and factors involved in discordant responses to highly active antiretroviral treatment in a closely followed cohort of treatment-naïve HIV-infected patients. J Clin Virol 2005, 33:110-115.
14. The creation of a large UK-based multicentre cohort of HIV infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004, 5:115-124. The UK Collaborative HIV Cohort Steering Committee.
15. Gazzard B, Anderson T, Babiker A. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
16. Hunt PW, Deeks SG, Rodriguez B. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003, 17:1907-1915.
17. Viard JP, Mocroft A, Chiesi A. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA Study. J Infect Dis 2001, 183:1290-1294.
18. Dronda F, Moreno S, Moreno A, Casado JL, Perez Elias MJ, Antela A. Long-term outcomes among antiretroviral-naïve human immunodeficiency virus-infected patients with small increases in CD4 cell counts after successful virologic suppression. Clin Infect Dis 2002, 35:1005-1009.
19. Losso M, Abrams D. and the INSIGHT ESPRIT Study Group., Effect of interleukin-2 on clinical outcomes in patients with a CD4 cell count of 300/mm: primary results of the ESPRIT Study. Montreal, Canada, February 2009 [Abstract 90aLB]
20. Levy Y. and the SILCAAT Scientific Committee., Effect of interleukin-2 on clinical outcomes in patients with CD4 cell count 50 to 299/mm: primary results of the SILCAAT Study. Montreal, Canada, February 2009 [Abstract 90bLB]